Atrium Therapeutics (RNA) director Gallagher granted RSUs and 205,000-share option
Rhea-AI Filing Summary
Atrium Therapeutics, Inc. director and officer Kathleen P. Gallagher reported receiving equity awards as part of her compensation. She was granted 102,500 shares of common stock in the form of restricted stock units, with each unit representing one future share of common stock, subject to vesting.
Gallagher was also granted a stock option for 205,000 shares of common stock at an exercise price of $14.30 per share. Twenty-five percent of both the RSUs and the option vest on March 20, 2027, with the remaining portions vesting over subsequent years, contingent on her continued service. After these grants, she directly owns 131,361 shares of common stock and holds the full 205,000-share stock option.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 102,500 shares
Net Buy
2 txns
Insider
Gallagher Kathleen P.
Role
See Remarks
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 205,000 | $0.00 | $0.00 |
| Grant/Award | Common Stock | 102,500 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 205,000 shares (Direct);
Common Stock — 131,361 shares (Direct)
Footnotes (2)
- F1. Represents an award of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Twenty-five percent (25%) of the RSUs shall vest on March 20, 2027, with the remaining RSUs vesting in three (3) substantially equal yearly installments each year thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date.
- F2. Twenty-five percent (25%) of the shares underlying this option shall vest and become exercisable on March 20, 2027, with the remaining shares vesting in thirty-six (36) substantially equal monthly installments each month thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date.
Key Figures
RSU grant size: 102,500 shares
Stock option grant: 205,000 shares
Option exercise price: $14.30/share
+3 more
6 metrics
RSU grant size
102,500 shares
Restricted stock units awarded to Gallagher
Stock option grant
205,000 shares
Option covering common stock granted to Gallagher
Option exercise price
$14.30/share
Exercise price for 205,000-share stock option
Shares owned after grant
131,361 shares
Common stock directly owned following RSU award
RSU initial vesting date
March 20, 2027
25% of RSUs vest on this date
Option expiration
April 20, 2036
Expiration date of stock option grant
Key Terms
restricted stock units ("RSUs"), Stock Option (Right to Buy), vest, exercise price, +1 more
5 terms
restricted stock units ("RSUs") financial
"Represents an award of restricted stock units ("RSUs"). Each RSU represents a contingent right..."
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
Stock Option (Right to Buy) financial
"Stock Option (Right to Buy) with an exercise price of 14.3000 per share..."
vest financial
"Twenty-five percent (25%) of the RSUs shall vest on March 20, 2027..."
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
exercise price financial
"conversion_or_exercise_price: "14.3000" for the Stock Option (Right to Buy)..."
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
underlying security financial
"underlying_security_title: "Common Stock", underlying_security_shares: "205000.0000"..."
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider transaction did Atrium Therapeutics (RNA) report for Kathleen P. Gallagher?
Atrium Therapeutics reported that Kathleen P. Gallagher received equity compensation grants. She was awarded restricted stock units covering 102,500 shares of common stock and a stock option for 205,000 shares, both vesting over time based on continued service with the company.
How many Atrium Therapeutics (RNA) RSUs were granted to Kathleen P. Gallagher?
Kathleen P. Gallagher received 102,500 restricted stock units. Each RSU represents a contingent right to receive one share of Atrium Therapeutics common stock, subject to vesting conditions tied to her continued service with the company over several years.
What are the terms of Kathleen P. Gallagher’s stock option grant at Atrium Therapeutics (RNA)?
Gallagher received a stock option covering 205,000 shares of Atrium Therapeutics common stock at an exercise price of $14.30 per share. The option vests over time, starting March 20, 2027, contingent on her ongoing service with the company.
When do Kathleen P. Gallagher’s Atrium Therapeutics (RNA) RSUs begin vesting?
Twenty-five percent of Gallagher’s RSUs vest on March 20, 2027. The remaining RSUs vest in three substantially equal yearly installments after that date, provided she continues to serve Atrium Therapeutics on each scheduled vesting date.
How does the vesting schedule work for Kathleen P. Gallagher’s Atrium Therapeutics (RNA) stock option?
For Gallagher’s stock option, 25% of the underlying 205,000 shares vest and become exercisable on March 20, 2027. The balance vests in 36 substantially equal monthly installments thereafter, conditioned on her continued service with Atrium Therapeutics.